PD39: Prostate Cancer: Detection & Screening V

Podium Session Moderator(s)

• 

  Daniel Barocas, MD

  Vanderbilt University Medical Center
• 

  Stacy Loeb, MD

  New York University and Manhattan VA

Presentations:

• 7:00 AM – 7:10 AM CST

  PD39-01: Prostate Cancer Screening During the COVID-19 Pandemic Across Demographic Groups
  

  Podium Presenter: Shyam Patnaik, MD
• 7:10 AM – 7:20 AM CST

  PD39-02: The Capio S:t Goran Model for Prostate Cancer Diagnosis using Stockholm3, Magnetic Resonance Imaging and Targeted Biopsies
  

  Podium Presenter: Thorgerdur Palsdottir
• 7:20 AM – 7:30 AM CST

  PD39-03: Integration of Polygenic risk score (PRS) with multiparametric MRI in men at risk for clinically significant prostate cancer
  

  Podium Presenter: Ikenna Madueke
• 7:30 AM – 7:40 AM CST

  PD39-04: mpMRI of the prostate in patients carrying a high clinical risk of prostate cancer diagnosis: is this imaging test necessary for diagnostic purposes in this subset of patients?
  

  Podium Presenter: Armando Stabile – San Raffaele Hospital Milan Italy
• 7:40 AM – 7:50 AM CST

  PD39-05: Impact of MRI-Targeting on Pathologic Upgrading and Downgrading at Prostatectomy: A Systematic Review and Meta-Analysis
  

  Podium Presenter: Ilon Weinstein (he/him/his)
• 7:50 AM – 8:00 AM CST

  PD39-06: Integrating Index lesion volume to better classify men with indolent prostate cancer among patients with intermediate risk disease. Results from a large, multi-institutional series
  

  Podium Presenter: Armando Stabile
• 8:00 AM – 8:10 AM CST

  PD39-07: Can we stop doing systematic biopsies in men with PIRADS/LIKERT 5 lesions on Multi Parametric Magnetic Resonance Imaging? An analysis from a multicentre prospective dataset of over 800 patients
  

  Podium Presenter: Jonathan Aning
• 8:10 AM – 8:20 AM CST

  PD39-08: Inter-center variability in positive predictive values of PIRADS score in patients undergoing prostate biopsy: results from the PROMOD Study Group.
  

  Podium Presenter: Marco Finati, MD (he/him/his) – University of Foggia - Dept. of Urology
• 8:20 AM – 8:30 AM CST

  PD39-09: Impact of Prostate Imaging Quality (PI-QUAL) score on the detection of clinically significant prostate cancer in men undergoing MRI-targeted biopsy
  

  Podium Presenter: Giorgio Brembilla
• 8:30 AM – 8:40 AM CST

  PD39-10: The association between PSA density and the detection of clinically significant prostate cancer across all PIRADS scores in men with positive mpMRI. When PSA density can help avoiding prostate biopsy?
  

  Podium Presenter: Francesco Pellegrino, MD – IRCCS San Raffaele
• 8:40 AM – 8:50 AM CST

  PD39-11: Effect of Shared Decision Making on Racial and Ethnic Disparity in Prostate Cancer Screening: Results from a National Behavioral Survey
  

  Podium Presenter: Nicola Frego, MD
• 8:50 AM – 9:00 AM CST

  PD39-12: Impact of Prostate-Specific Antigen testing pattern on cancer mortality among Black and White men diagnosed with prostate cancer: A large, urban health system cohort analysis
  

  Podium Presenter: Matthew James Davis, MD, MBA